Glenmark Pharmaceuticals Limited
GLENMARK
Clasificación en acciones
#2763
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Precio por acción
$24.28
Capitalización bursátil
$6.85B
Cambio (1 día)
-0.46%
Cambio (1 año)
15.18%
País
IN
Comercio Glenmark Pharmaceuticals Limited (GLENMARK)
Categoría
Healthcare
Ingresos de Glenmark Pharmaceuticals Limited (GLENMARK)
Ingresos en Jun 2026 TTM: $1.96B
Según los últimos informes financieros de Glenmark Pharmaceuticals Limited, los ingresos actuales de la empresa (TTM) son $1.96B. En 2024, la empresa obtuvo unos ingresos de $1.52B un aumento con respecto a los ingresos del año 2023, que fueron de $1.42B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Glenmark Pharmaceuticals Limited desde 2004 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.96B | 25.27% |
| 2025 | $1.56B | 3.03% |
| 2024 | $1.52B | 6.93% |
| 2023 | $1.42B | -12.51% |
| 2022 | $1.62B | 8.43% |
| 2021 | $1.49B | 5.68% |
| 2020 | $1.41B | -0.43% |
| 2019 | $1.42B | 1.94% |
| 2018 | $1.39B | -0.46% |
| 2017 | $1.40B | 22.48% |
| 2016 | $1.14B | 8.80% |
| 2015 | $1.05B | 5.93% |
| 2014 | $991.82M | 8.31% |
| 2013 | $915.73M | 15.49% |
| 2012 | $792.91M | 19.82% |
| 2011 | $661.74M | 18.85% |
| 2010 | $556.78M | 33.58% |
| 2009 | $416.81M | -16.99% |
| 2008 | $502.10M | 73.91% |
| 2007 | $288.72M | 69.74% |
| 2006 | $170.10M | 21.35% |
| 2005 | $140.17M | 59.84% |
| 2004 | $87.69M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 237.78% |
IN
|
